ESR1 and breast cancer: Interestingly, simultaneous exposure to both types of disruptors, naringenin and BPA, has been studied in the development of breast cancer, and naringenin had an antagonistic effect on ERα associated with proliferation processes even in the presence of simultaneous exposure to BPA [13,14,15].